Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

METHODS: The medical data of 47 patients with refractory bone and soft tissue sarcoma, who received anlotinib from January 2019 to December 2020, were retrospectively collected. The overall response rate (ORR) and disease control rate (DCR) were evaluated according to the solid tumor response evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Meng, Zhu, Jie, Zhou, Guangxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388280/
https://www.ncbi.nlm.nih.gov/pubmed/35991143
http://dx.doi.org/10.1155/2022/3287961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388280/
https://www.ncbi.nlm.nih.gov/pubmed/35991143
http://dx.doi.org/10.1155/2022/3287961

Ejemplares similares